title: Should warfarin and heparins be replaced by the new oral anticoagulants?
abstract: The results of phase 3 clinical trials of the new oral anticoagulants portray them as a promising new class of drugs with potential to replace the conventional anticoagulants. However, the transition from conventional to new oral anticoagulants will be gradual because of the deep seated roots of the conventional drugs in clinical practice and the high cost of the new agents.
authors.affiliation: Medical Student at Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
authors.forename: M S
authors.initials: MS
authors.lastname: Farooq
authors.affiliation: Medical Student at Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
authors.forename: M Z
authors.initials: MZ
authors.lastname: Farooq
authors.affiliation: Medical Student at Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
authors.forename: S
authors.initials: S
authors.lastname: Khan
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D006493:Heparin